FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $153.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-13.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-05-13
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $153.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2013-03-31 | $153.00K 10-Q · filed 2013-05-13 | |
| 2012-12-31 | $95.00K 10-Q · filed 2013-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |